{"nctId":"NCT00159783","briefTitle":"40 Week Extension Study Of Asenapine and Olanzapine For Bipolar Disorder (A7501007)(COMPLETED)(P05857)","startDateStruct":{"date":"2005-07"},"conditions":["Bipolar Disorder"],"count":218,"armGroups":[{"label":"Asenapine","type":"EXPERIMENTAL","interventionNames":["Drug: asenapine"]},{"label":"Olanzapine","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Olanzapine"]}],"interventions":[{"name":"asenapine","otherNames":["Org 5222"]},{"name":"Olanzapine","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Have completed asenapine 3-week and 9 -week studies for the treatment of an acute manic or mixed episode and not had any major protocol violations..\n\nExclusion Criteria:\n\n* Patients with unstable medical conditions or clinically significant laboratory\n\nabnormalities.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Participants Who Experienced Adverse Event(s)","description":"Adverse event (AE) data, both serious and non-serious, were collected. Serious AEs were also collected up to 30 days post last dose of study drug.\n\nAn AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product. It does not necessarily have to have a causal relationship with this treatment.\n\nAn AE is defined as serious if it results in death, is life-threatening, requires in-patient hospitalization or prolongs existing hospitalization, results in persistent or significant disability/incapacity, or is a congenital anomaly/birth defect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"68","spread":null},{"groupId":"OG002","value":"85","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Abnormal Physical Examination Findings","description":"Physical exam (PE) included assessment of general appearance, skin, head, eyes, ears, nose, throat, lungs, blood pressure, cardiac rhythm \\& rate, neurologic status, and abdomen. The findings were deemed to be normal/abnormal based on the clinical judgment of the investigator.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Abnormal Electrocardiogram","description":"This is the number of participants with electrocardiogram (ECG) adverse events.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]}]},{"type":"PRIMARY","title":"Body Weight","description":"Weight change from baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81.4","spread":"19.94"},{"groupId":"OG001","value":"68.1","spread":"17.22"},{"groupId":"OG002","value":"72.0","spread":"19.96"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":"5.95"},{"groupId":"OG001","value":"3.5","spread":"6.65"},{"groupId":"OG002","value":"6.0","spread":"6.59"}]}]}]},{"type":"PRIMARY","title":"Extrapyramidal Symptoms [EPS]","description":"EPS was assessed using the (1) involuntary movement scale \\[AIMS\\], (2) Barnes Akathisia Rating Scale \\[BARS\\], and (3) Simpson Angus Rating Scale SARS.\n\nAIMS score range 0-4; higher scores indicate greater symptom severity.\n\nBARS score rang 0-9; higher scores indicate greater severity of akathisia.\n\nSARS score range 0-40; higher scores indicate greater degree of Parkinsonism.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"1.37"},{"groupId":"OG001","value":"0.1","spread":"0.60"},{"groupId":"OG002","value":"0.0","spread":"0.14"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"1.21"},{"groupId":"OG001","value":"0.2","spread":"0.77"},{"groupId":"OG002","value":"0.1","spread":"0.55"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"1.72"},{"groupId":"OG001","value":"0.2","spread":"1.36"},{"groupId":"OG002","value":"0.3","spread":"1.15"}]}]}]},{"type":"PRIMARY","title":"Concomitant Medications","description":"Concomitant medications are any medications taken on or after the date of first dose of double-blind study drug through the date of\n\nlast dose of double-blind study drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"21","spread":null},{"groupId":"OG002","value":"31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"58","spread":null},{"groupId":"OG002","value":"76","spread":null}]}]}]},{"type":"PRIMARY","title":"Abdominal Girth","description":"Change in abdominal girth from baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91.1","spread":"14.20"},{"groupId":"OG001","value":"86.8","spread":"14.79"},{"groupId":"OG002","value":"89.4","spread":"14.78"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.0","spread":"6.84"},{"groupId":"OG001","value":"2.6","spread":"6.87"},{"groupId":"OG002","value":"5.0","spread":"7.89"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Markedly Abnormal Vital Sign Changes","description":"Vital signs measured: sitting blood pressure, heart rate.\n\nDefinitions:\n\nMarkedly abnormal decreases: heart rate (HR) - if ≤50 bpm and decrease from baseline of ≥15 beats per minute (bpm); systolic blood pressure (SBP) - if ≤90 mm Hg and decrease from baseline of ≥20 mm Hg; diastolic blood pressure (DBP) - if ≤50 mm Hg and decrease from baseline of ≥15 mm Hg.\n\nMarkedly abnormal increases: HR - if ≥110 bpm and increase from baseline of ≥15 bpm; SBP - if ≥180 mm Hg and increase from baseline of ≥20 mm Hg; DBP - if ≥105 mm Hg and increase from baseline of ≥15 mm Hg.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"11","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Laboratory Values Outside Normal Range","description":"Normal ranges were provided by the central laboratory.\n\nBiochemistry = electrolytes, creatine kinase, liver enzymes, blood urea nitrogen, creatinine, alkaline phosphatase, protein, albumin\n\nMetabolic chemistry = cholesterol, glucose, triglycerides, glycosylated hemoglobin\n\nEndocrinology/miscellaneous = insulin, prolactin\n\nHematology = hemoglobin, red blood cell count, white blood cell count, platelets, hematocrit, neutrophils, lymphocytes, monocytes, eosinophils, basophils","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"76","spread":null},{"groupId":"OG002","value":"115","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"32","spread":null},{"groupId":"OG002","value":"96","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"35","spread":null},{"groupId":"OG002","value":"39","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"90","spread":null},{"groupId":"OG002","value":"83","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":32},"commonTop":["Insomnia","Weight increased","Depression","Sedation","Fatigue"]}}}